Literature DB >> 11585406

Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy.

Y Aoki1, H Kase, M Watanabe, T Sato, H Kurata, K Tanaka.   

Abstract

OBJECTIVE: This study was performed to assess the prognostic factors and patterns of recurrence in stage III endometrial carcinoma treated with surgery and adjuvant chemotherapy.
METHODS: A retrospective review of 61 stage III endometrial carcinoma patients treated between 1988 and 1998 at Niigata University Hospital was performed. All patients underwent surgery, followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophosphamide. Multivariate analysis was performed for the prognostic factors and actuarial techniques were used for the survival and recurrence rates.
RESULTS: The 5-year disease-free survival was 78.6%. Multivariate analysis revealed deep myometrial invasion and lymph-vascular space involvement correlated significantly with disease-free survival. Based on these two factors, the patients could be divided into low-risk and high-risk groups. The 5-year disease-free survival for the low-risk group was 100%, which was significantly better than the 59.1% for the high-risk group. Disease recurrence occurred in 13 of 30 high-risk patients, and there was no recurrence in the 31 low-risk patients. Looking at the patterns of recurrence for the high-risk group by lymph node metastasis, 5 recurrences were locoregional, 1 was locoregional/distant, and 1 was distant in 16 node-positive high-risk patients. In 14 node-negative patients, 5 had distant and 1 had locoregional/distant recurrences.
CONCLUSIONS: The locoregional failure in the node-positive high-risk group deserves further attention. For improvement of locoregional control, it may be worthwhile to consider new strategies. The role of new adjuvant chemotherapy should be investigated to control distant failure in node-negative high-risk patients. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585406     DOI: 10.1006/gyno.2001.6321

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer.

Authors:  Kentaro Nakayama; Yutaka Nagai; Masako Ishikawa; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-04-24       Impact factor: 3.402

Review 2.  Endometrial cancer: treatment of nodal metastases.

Authors:  D Scott McMeekin; Todd Tillmanns
Journal:  Curr Treat Options Oncol       Date:  2003-04

3.  Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer.

Authors:  Lisa N Abaid; Mark A Rettenmaier; John V Brown; John P Micha; Alberto A Mendivil; Marie A Wabe; Bram H Goldstein
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401

4.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial.

Authors:  R Maggi; A Lissoni; F Spina; M Melpignano; P Zola; G Favalli; A Colombo; R Fossati
Journal:  Br J Cancer       Date:  2006-07-25       Impact factor: 7.640

5.  Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?

Authors:  Chunyan Lan; Xin Huang; Qidan Huang; Yin Wang; Haifeng Gu; Yong Li; Jihong Liu
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

6.  Cancer of the endometrium: current aspects of diagnostics and treatment.

Authors:  Karsten Münstedt; Phillip Grant; Joachim Woenckhaus; Gabriele Roth; Hans-Rudolf Tinneberg
Journal:  World J Surg Oncol       Date:  2004-07-21       Impact factor: 2.754

7.  microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway.

Authors:  Takashi Mitamura; Hidemichi Watari; Lei Wang; Hiromi Kanno; Makiko Kitagawa; Mohamed Kamel Hassan; Taichi Kimura; Mishie Tanino; Hiroshi Nishihara; Shinya Tanaka; Noriaki Sakuragi
Journal:  Mol Cancer       Date:  2014-04-29       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.